To analyze the clinical characteristics and related factors of a case report of anaphylactic shock induced by bevacizumab and provide safe references for clinical prescriptions. The patient received single-agent chemotherapy with bevacizumab for the 10th time for right lung adenocarcinoma, which presented with symptoms such as palpitation, shortness of breath, cyanosis of the lips, decreased pulse oxygen saturation, increased heart rate, undetectable blood pressure, transient convulsions and transient cardiac arrest. After rescue, the patient recovered and stoped the treatment of bevacizumab monoclonal antibody. Bevacizumab has a low incidence of anaphylaxis, however the tumor patients with multiple courses of treatment should be alert to severe/rare allergic reactions. Therefore, it is recommended to use it in an environment with rescue facilities.

1.国家药品不良反应监测中心. 药品不良反应报告和监测工作手册[S]. 2012.

2.高琦,段菊,徐保平,等.世界过敏组织严重过敏反应指导意见2020解读[J]. 中华实用儿科临床杂志, 2021, 36(6): 431-437. [Gao Q, Duan J, Xu BP, et al. Interpretation of World Allergy Organization anaphylaxis guidance 2020[J]. Chinese Journal of Applied Clinical Pediatrics, 2021, 36(6): 431-437.] DOI: 10.3760/cma.j.cn101070-20210203-00152.

3.美国卫生及公共服务部.常见不良事件评价标准（CTCAE）5.0 版[EB/OL]. (2017-11-27) [2021-06-20].http://guide. medlive.cn/.

4.Cortes J, Calvo V, Ramírez-Merino N, et al. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis[J]. Ann Oncol, 2012, 23(5): 1130-1137. DOI: 10.1093/annonc/mdr432.

5.齐磊,韩青兵,王可.贝伐珠单抗导致心肌梗死一例[J]. 中国呼吸与危重监护杂志, 2018, 17(6): 622-623. [Qi L, Han QB, Wang K. A case of myocardial infarction caused by bevacizumab[J]. Chinese Journal of Respiratory and Critical Care Medicine, 2018, 17(6): 622-623.] DOI: 10.7507/1671-6205.201703035.

6.余文韬,王怡鑫,蒋刚.贝伐珠单抗不良反应的文献计量分析[J].中国药房, 2017, 28(2): 190-193. [Yu WT, Wang YX, Jiang G. Bibliometric analysis of bevacizumab-induced ADR[J]. China Pharmacy, 2017, 28(2): 190-193.] DOI: 10.6039/j.issn.1001-0408.2017.02.12.

7.裘琳, 刘异, 侯黎伟, 等.贝伐珠单抗治疗恶性肿瘤相关不良反应回顾性分析[J]. 药物流行病学杂志, 2019, 28(2): 118-121. [Qiu L, Liu Y, Hou LW, et al. Retrospective clinical analysis of adverse reactions of bevacizumab in the treatment of malignant tumor[J]. Chinese Journal of Pharmacoepidemiology, 2019, 28(2): 118-121.] DOI: 10.19960/j.cnki.issn1005-0698.2019. 02.010.

8.王明媚,马建丽,王心慧,等. 117 例贝伐珠单抗注射液致药品不良反应的特点分析[J]. 中国医院用药评价与分析, 2020, 20(7): 872-875. [Wang MM, Ma JL, Wang XH, et al. Analysis of 117 cases of adverse drug reactions induced by bevacizumab injection[J]. Evaluation and Analysis of Drug-Use in Hospitals of China, 2020, 20(7): 872-875.] DOI: 10.14009/j.issn.1672-2124.2020.07.026.

9.BC Cancer Agency. Cancer drug manual, drug name: bevacizumab[DB/OL]. (2016) [2020-05-04]. http://www.bccancer.bc.ca/drugdatabase-site/Drug20%Index/Bevacizumab-monograph.pdf.

10.US Food and Drug Administration. FDA labels for bevacizumab (AVASTIN)[DB/OL]. (2019) [2019-08-17]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125085s331lbl.pdf.

11.Amit D, Kishore R, Vallish BN. Real world safety of bevacizumab in cancer patients: a systematic literature review of case reports[J]. Int J Risk Saf Med, 2021, 32(3): 163-173. DOI: 10.3233/JRS-194051.

12.Rombouts MD, Swart EL, Eertwegh AJ, et al. Systematic review on infusion reactions to and infusion rate of monoclonal antibodies used in cancer treatment[J]. Anticancer Res, 2020, 40(3): 1201-1218. DOI: 10.21873/anticanres.14062.

13.Vultaggio A, Petroni G, Pratesi S, et al. How the immune system responds to therapeutic biological agents[J]. J Int Med Res, 2016, 44(Suppl 1): 38-42. DOI:  10.1177/0300060515593248.

14.González-Bravo L, Laiseca García J, Alonso-Díaz-de-Durana MD, et al. Anaphylactic reactions with three non-related drugs (gadoteridol, paclitaxel, bevacizumab) in a patient with severe comorbidities[J]. J Investig Allergol Clin Immunol, 2022, 32(2): 161-163. DOI: 10.18176/jiaci.0729.

15.Castells M. Drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: The role of desensitizations[J]. Front Immunol, 2017, 8(8): 1472. DOI:  10.3389/fimmu.2017.01472.

16.Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy[J]. Oncologist, 2008, 13(6): 725-732. DOI: 10.1634/theoncologist.2008-0012.

17.Prussin C, Metcalfe DD. 5. IgE, mast cells, basophils, and eosinophils[J]. J Allergy Clin Immunol, 2006, 117(2 Suppl Mini-Primer): S450-456. DOI: 10.1016/j.jaci.2005.11.016.

18.Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions[J]. Oncologist, 2007, 12(5): 601-609. DOI: 10.1634/theoncologist.12-5-601.